Health-Related Quality of Life, Treatment Satisfaction, Adherence and Persistence in β-Thalassemia and Myelodysplastic Syndrome Patients with Iron Overload Receiving Deferasirox: Results from the EPIC Clinical Trial
Table 2
Mean (SD) SF-36 domain and summary scores among MDS patients according to prior ICT history.
Baseline mean (SD)
EOS mean (SD)
Reference MDS population (): mean (SD)
Age-matched UK norms: mean (SD)
Prior ICT (–62)
ICT Naïve (-35)
Prior ICT (–40)
ICT Naïve (–35)
Physical functioning
48.1
77.42
53.60
44.56
47.43
48.79
(30.6)
(25.38)
(21.35)
(17.94)
(24.39)
(23.29)
Role-physical
39.2
78.16
36.39
26.43
30.21
29.66
(42.5)
(28.11)
(39.21)
(36.85)
(40.90)
(35.60)
Bodily pain
66.6
71.52
65.61
64.69
63.23
59.77
(31.2)
(26.46)
(27.43)
(27.16)
(28.53)
(31.85)
General health
41.5
66.24
42.70
40.72
37.78
41.55
(21.3)
(22.57)
(18.94)
(20.00)
(20.01)
(15.92)
Vitality
50.6
57.79
43.25
37.35
42.89
40.20
(25.3)
(21.28)
(19.02)
(15.92)
(24.10)
(16.81)
Social functioning
67.0
81.08
68.55
71.07
62.18
63.21
(29.6)
(26.14)
(29.75)
(23.24)
(25.57)
(21.21)
Role-emotional
59.0
84.11
57.18
61.90
41.23
51.96
(41.4)
(24.41)
(44.05)
(41.34)
(43.45)
(45.83)
Mental health
72.3
73.84
66.78
69.06
60.07
64.47
(20.9)
(19.35)
(22.34)
(18.54)
(22.85)
(23.01)
Physical component summary
35.7
44.47
36.97
33.10
36.21
35.11
(11.7)
(12.32)
(8.48)
(8.31)
(8.70)
(10.80)
Mental component summary
48.9
52.28
46.32
48.49
42.14
45.27
(12.6)
(9.89)
(12.02)
(10.04)
(11.61)
(11.97)
Transfusion-dependent MDS patient reference data reported by Jansen et al. [17]; UK norms from Jenkinson et al. [42] and direct email communications from Dr. Jenkinson on Oct 24, 2011 with age-specific norms.
